Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title |
Type |
$ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Enhanced Mitochondrial Function to Increase Effectiveness of Post-Stroke Rehabilitation (IPA for Helena Morrison) | Contract | $37,164.14 | Research | Rick Schnellmann | Pharmacy Administration | United States Department of Veterans Affairs | 05/2020 |
| Yuma County Contact Tracing | Contract | $252,435.00 | Other Sponsored Activity | Cecilia Rosales | Public Hlth Pract & Trans Rsch | Yuma County Public Health Services District | 07/2020 |
| Octagam 10% Gam10-09 Study | Contract | $64,539.00 | Research | Sydney Rice | Pediatrics | Octapharma AG | 03/2020 |
| In Vivo Screening of Candidate Therapeutic Antibodies in Preclinical Models of Chorioamnionitis-Related Prematurity (ChorP) and Pulmonary Hypertension (PH) | Contract | $31,026.00 | Research | Mohamed Ahmed | Pediatrics | Aqualung Therapeutics, Corp. | 02/2020 |
| Epigenetic Evaluation of WUI Firefighters | Contract | $380,478.00 | Research | Jefferey Burgess | Community Environment & Policy | Bureau Veritas North America | 05/2020 |
| Salary support for Amani Morgan Mikail | Contract | $119,988.00 | Other Sponsored Activity | Madhan Shanmugasundaram | Sarver Heart Center | Biomedical Research and Education Foundation of Southern Arizona | 01/2020 |
| The Crucial Role of HCN2 Channels in Inflammatory and Neuropathic Pain | Contract | $54,277.03 | Research | Rajesh Khanna | Pharmacology | Fondazione Cariplo (Italy) | 04/2020 |
| P-glycoprotein Mediated Transport of CNS Therapeutics at the Blood-Brain Barrier | Contract | $34,128.00 | Research | Patrick Ronaldson | Pharmacology | MapLight Therapeutics, Inc. | 03/2020 |
| In Vivo Screening of Candidate Therapeutic Antibodies in Preclinical Models of Prostate Cancer | Contract | $31,231.00 | Research | Anne Cress | Cellular & Molecular Medicine | Aqualung Therapeutics, Corp. | 02/2020 |
| A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | Contract | $91,617.50 | Clinical Trial | Pavani Chalasani | Cancer Center Division | Zeno Pharmaceuticals, Inc. | 01/2020 |
| MHC Class II Presentation in Melanoma: Impact on Immune Recognition | Contract | $250,000.00 | Research | Karen Hastings | COM Phx Basic Medical Sci | University of Arizona Foundation | 08/2020 |
| Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Severe Influenza Associated Illness in US Children | Contract | $44,500.00 | Research | Mary Gaspers | Pediatrics | Boston Children's Hospital | 05/2020 |
| A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors | Contract | $458,027.74 | Clinical Trial | Hani Babiker | Cancer Center Division | Parexel International Corporation | 01/2020 |
| Understanding the Patient-Centered Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas: A Pilot Trial | Contract | $25,000.00 | Research | Tze-Woei Tan | Surgery | American Society of Diagnostic and Interventional Nephrology | 04/2020 |
| A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... | Contract | $273,767.50 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Janssen Research & Development, LLC | 01/2020 |
| A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome (ARDS.. | Contract | $168,927.92 | Clinical Trial | Marilyn Glassberg Csete | COM Phx Internal Medicine | Kinevant Sciences, Inc. | 08/2020 |
| Accuracy of Arthroscopic vs. Open Reduction of Ankle Syndesmosis Injuries | Contract | $5,000.00 | Research Training | Aditya Manoharan | Orthopaedic Surgery | Orthopaedic Research and Education Foundation | 04/2020 |
| Octapharma's Octagam 10% Gam10-09 Study | Contract | $64,944.00 | Research | Michael Daines | Asthma/Airway Disease Rsch Ctr | Octapharma Pharmazeutika Produktionsgesellschaft mbH (Austria) | 08/2020 |
| A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-3 | Contract | $80,418.76 | Clinical Trial | Franz Rischard | Medicine | Complexa, Inc. | 01/2020 |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | Contract | $607,532.16 | Clinical Trial | Sachin Chaudhary | Medicine | Covance, Incorporated | 08/2020 |
| Animal Purchasing and Husbandry Service Agreement in Support of Protocol 19-3178 "5-HT1F Receptor Agonism as a Novel Therapeutic Strategy Following Spinal Cord Injury" | Contract | $75,449.72 | Research | Rick Schnellmann | Pharmacy Administration | United States Department of Veterans Affairs | 07/2020 |
| SAVAHCS: IPA for Josh Crossman | Contract | $41,154.48 | Research | Rick Schnellmann | Pharmacy Administration | United States Department of Veterans Affairs | 02/2020 |
| Prenatal Coordinated Care Pilot Program | Contract | $8,426.00 | Research | Maria Manriquez-Sanchez | COM Phx Obstetrics&Gynecology | Superior Court of Arizona in Maricopa County | 08/2020 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Efficacy and Safety of Anamorelin HCL for the Treatment OF Malignancy Associated Weight Loss and Anorexia... | Contract | $42,626.00 | Clinical Trial | Charles Hsu | Cancer Center Division | PSI Pharma Support America, Incorporated | 01/2020 |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with... | Contract | $1,278,228.50 | Clinical Trial | Charles Hsu | Radiation Oncology | Astrazeneca | 08/2020 |